The Pharma Data

OCTOBER 28, 2020

28, 2020 /PRNewswire/ — . Today’s data, involving an additional 524 patients from the ongoing Phase 2/3 trial, provides definitive final virology results and meets the clinical endpoint of reducing medical visits. Senior Vice President and Head of Global Clinical Development at Regeneron. TARRYTOWN, N.Y. ,

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

DECEMBER 3, 2020

4, 2020 08:00 UTC. Based on the positive Phase 1 results reported and the unprecedented need for COVID-19 vaccines, Clover and its partners are confident to enter late-stage clinical development for both adjuvanted vaccines. The Phase 1 clinical trial was funded by the Coalition for Epidemic Preparedness Innovations (CEPI).

Vaccine 52

Vaccine Immune Response Virus RNA 52

The Pharma Data

APRIL 15, 2022

Louis is being advanced toward Phase I human clinical trials to treat COVID-19. Designed computationally and refined in the laboratory, the new protein therapies thwarted infection by interfering with the virus’ ability to enter cells. This work was originally reported in 2020 in the journal Science. 2 omicron subvariant.

Treatment 52

Treatment Virus Laboratories Engineering 52

The Pharma Data

OCTOBER 31, 2020

1, 2020 /PRNewswire/ — TaiGen Biotechnology Company, Limited (“TaiGen”) ( Taiwan : 4157) announced today that U.S. The first US patent for TG-1000 was successfully prosecuted and granted by the United States Patent and Trademark Office on Jan 14 th , 2020. TAIPEI, Taiwan , Nov. View original content: [link].

FDA Approval 52

FDA Approval FDA Clinical Development Virus 52

The Pharma Data

NOVEMBER 11, 2020

12, 2020 14:00 UTC. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for SLV213 for the treatment of COVID-19 and has dosed the first subjects in a Phase 1 clinical study. Preclinical data show SLV213 is a potent inhibitor of SARS-CoV-2 infection.

Treatment 52

Treatment Small Molecule Virus Pharmacokinetics 52

The Pharma Data

OCTOBER 29, 2020

30, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT ® ) will be presented at the annual Fall Clinical Dermatology meeting taking place virtually October 29-November 1, 2020. vice president of immunology development at Lilly.

Therapies 52

Therapies Treatment Disease Clinical Trials 52

The Pharma Data

OCTOBER 27, 2020

28, 2020 /PRNewswire/ — Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces the formation of a new Scientific Advisory Board (SAB). OSLO, Norway , Oct. Fennel cover the key scientific focus areas of Targovax. Dean A.

Virus 52

Virus Engineering Clinical Development International 52

The Pharma Data

FEBRUARY 25, 2021

5 To date, ticks infected with the TBE virus have been identified in more than 35 countries across Europe and Asia. About TicoVac (TBE vaccine, whole virus inactivated). Singapore: Global Health Press; 2020. Accessed: May 2020. Tick-borne encephalitis virus vaccines, p 773–88. The Lancet. 2008;371(9627):1861-71.

FDA 52

FDA Vaccine Virus Clinical Trials 52

The Pharma Data

NOVEMBER 9, 2020

09, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease.

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

OCTOBER 15, 2020

. ASLAN appoints neurologist Professor Gavin Giovannoni as a scientific advisorto establish clinical development strategy in multiple sclerosis. Following an internal strategic review and noting changes in the AML treatment landscape, ASLAN will be focusing the future development of ASLAN003 in autoimmune disease.

Pharmaceuticals 40

Pharmaceuticals Cell Based Assays Clinical Development Treatment 40

Creative Biolabs

JULY 12, 2020

They are currently working with Boehringer Ingelheim to further identify and develop these antibodies. They are expected to enter clinical development later this year. This means that only minor changes are needed to effectively identify and neutralize the virus.

Immune Response 52

Immune Response Laboratories Clinical Trials Clinical Development 52

The Pharma Data

MARCH 26, 2021

Preclinical data suggest VIR-7831 targets a highly conserved epitope of the spike protein, which may make it more difficult for resistance to develop. About the VIR-7831 Clinical Development Programme. Preclinical data suggest it has the potential to both block viral entry into healthy cells and clear infected cells.

Treatment 52

Treatment FDA Vaccine Trials 52

The Pharma Data

AUGUST 7, 2020

In this light, Pharma IQ’s weekly round-up focuses on advancing therapies and clinical trials to combat Covid-19. A H1 2020 global sector report from The Alliance for Regenerative Medicine’s (ARM) detailed, trends and metrics in the gene, cell and tissue-based therapeutic sector in the midst of the Covid-19 pandemic.

Clinical Trials 52

Clinical Trials Trials Packaging Therapies 52

The Pharma Data

MARCH 29, 2022

13 People at increased risk of exposure to the SARS-CoV-2 virus could also benefit from protection with Evusheld. 1,3 The reduced Fc effector function aims to minimise the risk of antibody-dependent enhancement of disease – a phenomenon in which virus-specific antibodies promote, rather than inhibit, infection and/or disease.20.

Vaccine 52

Vaccine Virus Immune Response Trials 52

The Pharma Data

JUNE 26, 2021

The extensive Actemra/RoActemra RA IV clinical development programme included five phase III clinical studies and enrolled more than 4,000 people with RA in 41 countries. As soon as the novel SARS-CoV-2 virus was sequenced in early 2020, we got to work. On 13 March 2020 we became the first company to receive U.S.

FDA 40

FDA Treatment Clinical Trials Virus 40

The Pharma Data

JULY 29, 2021

for the same period in 2020. This was primarily driven by the impact of higher in-process research and development (“IPR&D”) expenses in the second quarter 2020 related to the Forty Seven, Inc. billion as of December 31, 2020. billion compared to the same period in 2020. Second Quarter 2021 Financial Results.

Science 52

Science Production Treatment FDA 52

The Pharma Data

OCTOBER 14, 2020

. Potential Development of Human Monoclonal Antibody Therapeutics to SARS-CoV-2. 15, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. Tonix is also developing TNX-2300* and TNX-2600*, live replicating vaccine candidates for the prevention of COVID-19, but using bovine parainfluenza as the vector.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

MARCH 11, 2021

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2, the virus that causes COVID-19.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

OCTOBER 30, 2020

30, 2020 /PRNewswire/ — The IDMC also recommends continuation of enrollment in the REGN-COV2 outpatient trial. About REGN-COV2 REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19. TARRYTOWN, N.Y. ,

Hospitals 52

Hospitals Virus Production Clinical Trials 52

The Premier Consulting Blog

JUNE 18, 2023

The information gleaned from these in silico models was used to design and test medicines against the virus, speed-up the vaccine discovery pipeline, predict any therapeutic failures, and minimize undesired effects. BMC Bioinformatics 2020, 21(Suppl 17):527 [link] Accessed April 4, 2023, at: [link] [2] Russo et al.

Drug Development 52

Drug Development Disease Clinical Trials Drugs 52

The Pharma Data

NOVEMBER 19, 2020

20, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces a progress update for its R&D program focused on the design and development of novel drugs targeting the SARS-CoV-2 coronavirus and to treat COVID-19. The program was initiated in April 2020. References.

Small Molecule 40

Small Molecule Structure Based Drug Design (SBDD) Molecular Biology International 40

The Pharma Data

SEPTEMBER 9, 2020

The proposed agreement is intended to provide a supply of 200 million doses and an option to purchase additional 100 million doses, with deliveries starting by the end of 2020, subject to regulatory approval. Deliveries would be starting by the end of 2020, subject to clinical success and regulatory authorization.

Vaccine 52

Vaccine Clinical Trials Trials Government 52

The Pharma Data

JANUARY 31, 2021

Gilead and Gritstone will develop an HIV-specific therapeutic vaccine using Gritstone’s proprietary prime-boost vaccine platform, comprised of self-amplifying mRNA (SAM) and adenoviral vectors, with antigens developed by Gilead. This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

The Pharma Data

NOVEMBER 1, 2020

Clinical Data Expected by End of Year. The scientific concept, to activate nasal mucosal immunity by nasally administered Foralumab, is to fight against the virus in the respiratory tract and lungs,” stated Dr. Shailubhai, CEO and CSO of Tiziana Life Sciences. Lancet 2020; 395: 497–506. About Foralumab.

Clinical Trials 52

Clinical Trials Trials Medical Schools Hospitals 52

The Pharma Data

AUGUST 15, 2021

Vivet Therapeutics is a clinical-stage emerging biotechnology company developing novel gene therapy treatments for rare, inherited metabolic diseases. Vivet’s lead program, VTX-801, is currently under clinical development. Columbus Venture Partners, Ysios Capital, Kurma Partners and Idinvest Partners.

Disease 52

Disease FDA Treatment Clinical Trials 52

The Pharma Data

JULY 21, 2021

Valneva and Pfizer entered into a collaboration agreement in April 2020 to co-develop VLA15 2. Positive top-line results have already been reported for two Phase 2 clinical trials of VLA15 in over 800 healthy adults. The two companies are working closely together on the next development steps. About VLA15.

Vaccine 52

Vaccine Disease Trials Protein Expression 52

The Pharma Data

DECEMBER 17, 2020

17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. ,

Hospitals 52

Hospitals Production Clinical Trials Therapies 52

The Pharma Data

APRIL 1, 2021

In July 2020, Tecartus became the first and only CAR T-cell therapy to receive accelerated approval from the FDA for the treatment of relapsed or refractory mantle cell lymphoma, based on overall response rate and durability of response.

Treatment 52

Treatment Virus Therapies FDA 52

The Pharma Data

OCTOBER 27, 2020

. This collaboration strengthens Novartis’ ongoing commitment to research and partner with other companies to find and develop treatment options for COVID-19 and make them available around the world as fast as possible. During the clinical development stage, Molecular Partners will provide clinical supply.

Therapies 52

Therapies Virus Treatment Clinical Trials 52

The Pharma Data

JANUARY 20, 2021

TSX: CRDL ) ( OTCQX: CRTPF ) is a clinical-stage biotechnology company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Cardiol Therapeutics Inc. (

Hospitals 52

Hospitals Trials International Clinical Trials 52

The Pharma Data

APRIL 27, 2021

We remain committed to moving as quickly and safely as possible to bring this vaccine to more people in Europe, as the deadly virus continues to wreak havoc across the continent.” This brings the total number of doses to be delivered to the EU to 600 million. “We said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “To

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

SEPTEMBER 15, 2020

On a non-risk adjusted basis, these opportunities collectively represent more than $15 billion (excluding 20vPnC) in potential incremental revenue for Pfizer from 2020 to 2025, as well as aggregate peak annual sales potential of $35 billion to $40 billion (including 20vPnC). BNT162 mRNA-based Vaccine Program. for RSV A and 18.0

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

The Pharma Data

NOVEMBER 29, 2020

30, 2020 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. Response to a two-dose schedule did not show an improvement compared to placebo, which is consistent with the low levels of CMV-neutralizing antibody in the two-dose group as well as with the T cell data reported in June 2020 for the two-dose group. 1 Gilbert C and Boivin G.

Vaccine 52

Vaccine Clinical Trials Disease Therapies 52

The Pharma Data

SEPTEMBER 9, 2020

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced preliminary preclinical data in mouse and non-human primate models from their BNT162b2 mRNA-based vaccine program against SARS-CoV-2, the virus that causes COVID-19 disease. The information contained in this release is as of September 9, 2020. billion doses by the end of 2021.

Vaccine 52

Vaccine RNA Clinical Trials Trials 52

The Pharma Data

AUGUST 20, 2020

These results informed the selection of the BNT162b2 candidate for the pivotal Phase 2/3 global study in up to 30,000 participants that started in July 2020, which has to date enrolled more than 11,000 participants, including in areas with significant SARS-CoV-2 transmission. The information contained in this release is as of August 20, 2020.

Vaccine 52

Vaccine Clinical Trials Trials Immune Response 52

The Pharma Data

OCTOBER 19, 2020

20, 2020 /PRNewswire/ — Caris Life Sciences® , a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that Winship Cancer Institute of Emory University (Winship) has joined Caris’ Precision Oncology Alliance (The Alliance/POA). IRVING, Texas and ATLANTA , Oct.

Clinical Trials 52

Clinical Trials RNA DNA Science 52

The Pharma Data

AUGUST 3, 2021

Quantum computing holds enormous potential for pharmaceutical research and development, particularly for early research processes in which Boehringer Ingelheim has a high level of expertise. Boehringer Ingelheim also remains committed to the search for potential therapeutics against the SARS-CoV-2 virus.

Research 52

Research Treatment Clinical Trials Production 52